Hematopoietic stem cell transplantation for sickle cell anemia.
Hematopoietic stem cell transplantation is the only therapy able to cure sickle cell anemia at the present time. So far, transplantations have been undertaken in approximatively 140 sickle cell patients all over the world, with good results. The selection of patients for transplantation remains a subject of dilemma because of the unpredictable course of the disease and the lack of valuable prognostic markers. The selection criteria accepted so far concern young patients under the age of 16, with a morbid course of the disease and having a HLA-compatible sibling. In Belgium, patients going back to their country of origin were also considered for transplantation. For 100 patients who underwent transplantation in Europe, the current Kaplan-Meier estimates of overall survival, event-free survival, and disease-free survival rates are 90%, 79%, and 81%, respectively. Benefits and side effects are analyzed.
Vermylen
C
C
Department of Pediatric Hematology, Cliniques Saint Luc, University of Louvain, Brussels, Belgium.
Cornu
G
G
D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000401:mortality / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007223:Infant; D018579:Patient Selection; D015996:Survival Rate; D016896:Treatment Outcome